A new genetic risk score that takes hundreds of different genetic variations into account may help predict who’s most likely to develop amyotrophic lateral sclerosis (ALS). The score needs to be validated in future studies before being used in the clinic, but could be important to stratify people according…
News
The French medtech company BrainTale has raised €4.5 million (about $4.9 million) to support the development of a noninvasive imaging analysis platform to help diagnose and monitor amyotrophic lateral sclerosis (ALS) and other neurological disorders. The platform, called BrainTale-care, is a digital medical platform that examines MRI scans…
Work into developing molecules that block microRNA-155 (miR-155) as potential treatments for amyotrophic lateral sclerosis (ALS) has advanced to the stage of testing candidate molecules in animal models of the disease. Initiated last year, the miR-155 project is a collaboration between scientists at Regulus Therapeutics and Brigham…
A Phase 3 clinical trial that’s testing FNP122, Ferrer’s oral formulation of edaravone, in people with amyotrophic lateral sclerosis (ALS) is now rolling participants into its open-label extension study. The ADORE trial (NCT05178810) is testing FNP122 against a placebo in about 300 patients across Europe whose…
VRG50635, an experimental oral therapy being developed by Verge Genomics for amyotrophic lateral sclerosis (ALS), was found to be safe and well-tolerated in healthy volunteers, new Phase 1 trial data show. Top-line data from the trial (ISRCTN14792372) also showed a promising tolerability and pharmacological profile supporting once-daily…
The Committee for Medicinal Products for Human Use (CHMP) has issued an opinion opposing Amylyx Pharmaceuticals’ bid for conditional European Union approval of AMX0035, its oral treatment to slow the progression of amyotrophic lateral sclerosis (ALS). The negative recommendation from the advisory committee, an arm of the…
The first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating VTX3232, Ventyx Biosciences’ investigational oral therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Top-line data from the trial are expected in the first half of 2024. “VTX3232 is our fourth internally discovered…
Magnetic stimulation restored the health of lab-grown motor neurons — the muscle-controlling nerve cells that die in amyotrophic lateral sclerosis (ALS) — derived from people with familial ALS, according to a proof-of-concept study. The approach improved several biological processes in motor neurons, including the movement of cellular components along…
Albrioza, the approved treatment for amyotrophic lateral sclerosis (ALS) formerly known as AMX0035, is one giant step closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Amylyx Pharmaceuticals. Amylyx has reached an agreement with the pan-Canadian Pharmaceutical Alliance, or pcPA —…
PEG10, an ancient, virus-like protein that supports the development of the placenta, appears to also participate in the nerve cell loss associated with amyotrophic lateral sclerosis (ALS), researchers discovered. ALS-causing mutations in the UBQLN2 gene were found to prevent the proper degradation of PEG10. This led to a…
Recent Posts
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type
- Grant funds new ALS treatment approach targeting TDP-43 pathway